Open AccessA Controlled Trial of Erenumab for Episodic Migraine
Author(s) -
Peter J. Goadsby,
Uwe Reuter,
Yngve Hallström,
Gregor Broessner,
Jo Bonner,
Feng Zhang,
Sandhya Sapra,
Hernàn Picard,
Daniel D. Mikol,
Robert Lenz
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1705848
Subject(s) - migraine , medicine , placebo , randomization , population , tolerability , calcitonin gene related peptide , sumatriptan , clinical trial , adverse effect , receptor , alternative medicine , pathology , environmental health , neuropeptide , agonist
We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom